Pioneering the first human protein-based cell-targeted delivery system
Safer, precise and more effective

For decades, medicine has faced complex diseases without distinguishing between healthy and diseased cells. Now we have the ability to engineer cells inside the human body, and it is already transforming thousands of lives.

The real bottleneck isn’t what to treat, but how to deliver the treatment.

Our mission is to change that.

OUR APPROACH

Instead of refining the systems that already exists, we built something entirely new, starting with a simple but radical question:

Can we design a therapeutic nanoparticle using only human proteins?

bioND
BIOMIMETIC NATURAL DELIVERY
Modular
Cellular Engineering
Platform
IN-VIVO • CELL-TARGETED • HUMAN PROTEIN-BASED
At DNAmic, we recognize the fundamental barriers that have long hindered progress in the development of next-generation molecular medicines. From the toxicity, inefficiency, and risks associated with viral vectors to the limited targeting capabilities and reduced effectiveness of non-viral systems, these challenges have constrained the potential of advanced medicine.
Our human-based engineering platform represents a pivotal leap in in-vivo cell engineering and reprogramming, designed to transcend these limitations.
Explore
JOIN US

Balancing ambition with openness

We specialize in cutting-edge cellular engineering and regenerative medicine, driven by a relentless pursuit of innovation. We are always eager to collaborate, exchange knowledge, and grow alongside fellow pioneers shaping the future of genetic and cellular therapies.

“ To everyone working on the next generation of genetic and cellular therapies, we offer a solution that removes the delivery challenge and accelerates the path to clinical impact.
The possibilities are vast, and the time to bring in vivo cellular engineering to its full potential is now.
Let’s build the future of medicine together. ”

Alfonso Fiz

CEO and CO-Founder DNAmic

Contact
MENU
Vision
Science
Company
Contact
SOCIALS
LinkedIn
@ 2025 DNAmic BioSystems